Navigation Links
Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Date:12/15/2008

SAN DIEGO, Dec. 15 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Ortho-McNeil) initiated under their partnership a first-in-human Phase 1 clinical trial of APD597, a novel oral drug candidate discovered by Arena that targets the glucose-dependent insulinotropic receptor (GDIR) for the treatment of type 2 diabetes. The GDIR was also discovered by Arena and has the potential to stimulate insulin release in response to increases in blood glucose.

"The GDIR is a promising and exciting target for the treatment of type 2 diabetes. We look forward to continuing to work with Ortho-McNeil on APD597 as it advances in the clinic," stated Jack Lief, Arena's President and Chief Executive Officer.

Ortho-McNeil's Phase 1 program will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of APD597 in single and multiple ascending dose studies in healthy volunteers. Ortho-McNeil's planned clinical studies will also include the evaluation of patients with type 2 diabetes.

Aboutthe Glucose-Dependent Insulinotropic Receptor (GDIR)

The GDIR is an orphan G protein-coupled receptor (GPCR), discovered by Arena. It is expressed in beta cells, the cells in the pancreas responsible for producing insulin in response to increases in blood glucose. The GDIR signals through a similar intracellular pathway as the GLP-1 receptor, with common downstream effects, but unlike the GLP-1 receptor, the GDIR has proven amenable to small molecule drug discovery. Stimulation of the GDIR is intended to more efficiently promote insulin release by beta cells in response to elevated blood glucose levels. In addition, the GDIR is expressed in cells other than pancreatic beta cells, such as endocrine cells in the gastrointest
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds ... its store . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ... upgrade and policy support, China,s ... years, with total market size rising from 3.28 billion ...
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... be an alternative therapy for Parkinson,s , NEW YORK, ... University Medical Center have reached a milestone in the development ... the limitations of current therapy. , The team, which received ... Foundation,s 2007 LEAPS (Linked Efforts to Accelerate Parkinson,s Solutions) ...
... Sept. 30 InteKrin Therapeutics Inc. announced today positive ... safety studies. Data will be presented at the ... Meeting in Vienna, Austria at 12:45 PM ... Officer, Linda Higgins, PhD, in a presentation "Chronic Cardiovascular ...
Cached Medicine Technology:Michael J. Fox Foundation-Funded Team Pursuing Glutamate-Based Treatment for Parkinson's Disease Hits Major Milestone 2InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting 2
(Date:4/24/2014)... a better understanding of drug interactions, which are a ... When two or more medications are taken at the ... of the other. Similarly, one drug may magnify ... a major cause of illness and hospitalization. However, ... of drug studies in humans. Limits come in ...
(Date:4/24/2014)... outcomes for parents who have a child born with ... recent study led by a researcher at the University ... life-changing and stress levels high, the vast majority of ... outcomes as well, a phenomenon known as posttraumatic growth. ... the American Journal of Orthopsychiatry . , "What ...
(Date:4/24/2014)... WINSTON-SALEM, N.C. April 24, 2014 ,Take me ... of apple slices and kale chips. The more likely ... of Crackerjacks. , Unfortunately for children who play ... may be contributing to weight problems, according to researchers ... in the current online edition of Childhood Obesity ...
(Date:4/24/2014)... 28, the Center for BrainHealth will bring together ... pressing brain-related challenges at its inaugural Brain Health ... Regeneration." Featured speakers will include Dr. Sandra Bond ... for BrainHealth, U.S. Senator Chuck Grassley (R-IA), U.S. ... Assistant Secretary for Policy and Early Learning, U.S. ...
(Date:4/24/2014)... and irrelevant, could offer an alternative to heart transplants ... Furtado, and her team from the Australian Regenerative Medicine ... fibroblast is a close relative to a cardiomyocyte, the ... research published today in Circulation Research , Dr ... due to their genetic program, and will aid in ...
Breaking Medicine News(10 mins):Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Parents of severely ill children see benefits as caregivers, says study 2Health News:Take the bat, leave the candy 2Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Boring cells could hold the key to heart disease 2
... But what about homosexual partnerships? Are they made for each ... a while, and now it seems like the battle lines ... ,The U.S. president, during a recent radio address, has ... Bush said 'This national question requires a national solution, and ...
... the London School of Medicine and Dentistry has called ... the UK//. Len Doyal a professor of medical ethics ... ,The professor believes that doctors should be able ... in an article that was published today in the ...
... an United nation official, a campaign to warn Indonesians ... year after the virus infected //the first of 49 people ... country in the world. ,According to John Budd, ... Jakarta, thousands of government workers and several members of ...
... and Jehangir Sabavala displayed their work on ‘Visual Trajectories’ ... held at Durban for a period of 3 weeks ... co-operation between Indian and South African Governments, an agreement ... African National Gallery (Iziko Sang) and National Gallery of ...
... The discovery of a 170cm tall adult human skeleton ... conspicuous', says Mishra. // ,'A lot of ... related to the culture, customs, lineage or gene-pool, birth, ... Mishra says., ,The Abhaipur site preserves evidence of ...
... become mandatory for the doctors to recommend the mothers of ... the first six months, excluding any solid foods. But that ... saying that feeding the babies on cereals in the earlier ... ,Jill Poole, M.D., assistant professor in the pulmonary, critical ...
Cached Medicine News:Health News:Differently Wired and Gay – Are They Children of a Lesser God 2Health News:Earlier Introduction of Solid Foods in Infants Could Prevent Wheat Allergy 2
... TF is a minimally invasive tension-free ... urinary incontinence resulting from urethral hypermobility ... The Stratasis TF Kit is designed ... retrograde placement. Supplied sterile in ...
Stratasis Urethral Sling is intended for implantation to reinforce soft tissues where weakness exists. Supplied sterile in peel-open packages. Intended for one-time use....
... Roadrunner, Bentson, or other flexible tipped wire ... a redundant or tortuous ureteral segment. The ... and beyond a ureteral stone, or possibly ... from the mucosal wall. Supplied sterile in ...
Used for retrograde pyelogram. The tip configuration occludes the ureteral orifice and stabilizes the catheter by temporarily wedging in the orifice. Supplied sterile in peel-open packages. Intended ...
Medicine Products: